🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#PORTOS biomarker guides radiation dose escalation in #ProstateCancer treatment. George Zhao, MD UW School of Medicine and Public Health & Alan Dal Pra, MD Sylvester Comprehensive Cancer Center join Alicia Morgans, MD, MPH Dana-Farber to discuss updates to the PORTOS trial and how it predicts radiation benefit in #PCa. #WatchNow >

Muchas gracias Oscar Tahuahua por el gran resumen del artículo

#CALYPSO trial: Savolitinib and durvalumab in advanced papillary #RenalCancer. Francesca Jackson-Spence Barts Experimental Cancer Medicine Centre joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss final overall survival data and circulating tumor DNA analysis for patients with advanced papillary renal cancer in the CALYPSO

🫣🫣🫣😳

Antibody–Drug Conjugates (ADCs) in SCLC All active agents in 2L/3L+ setting—DLL3, B7-H3, SEZ6, TROP2—summarized in one slide. Includes payloads, companies,trials, ORR/PFS/OS, and toxicity profile Which one you think is most promising one #OncoTwitter OncoAlert Yakup Ergün

ADCs are rapidly moving to earlier line treatment for breast cancer. Will likely reach the (neo)adjuvant setting soon. Here’s a recap of key ADC phase 3 trials expected to shape practice in the next future:

#PARASEC study reveals real-world treatment patterns after darolutamide in the #ARAMIS trial. 📽️ Zach Klaassen Georgia Cancer Center & Javier Puente IdISSC, IIS del Hospital Clínico San Carlos break down the PARASEC trial findings from the Spanish ARAMIS cohort. 🧠 Key takeaways: - 29% received no tx post-mCRPC - 63%

🆕article in press: Copenhagen Prospective Personalized Oncology (CoPPO) – Impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting doi.org/10.1016/j.anno…

177-Lutetium-PSMA vs Cabazitaxel: a real-world #mCRPC study. Mike Wenzel, BSc joins Neeraj Agarwal, MD, FASCO to discuss a real-world analysis of cabazitaxel vs. Lu-177 PSMA RLT in mCRPC. Findings from ~300 pts show longer PFS with Lu-177 (13 vs. 7 mos) & a trend toward OS benefit. Sequential

Managing BCG-unresponsive #BladderCancer: Balancing bladder preservation and cystectomy. Paolo Gontero & Maria Carmen Mir, MD, PhD join Ashish M. Kamat, MD, MBBS in a discussion addressing management approaches for BCG-unresponsive bladder cancer. #WatchNow on UroToday >

#EMBARK Trial: Treatment options for high-risk biochemical recurrence. Neal Shore, MD, FACS CURC and Zach Klaassen Georgia Cancer Center discuss treatment options for high-risk biochemical recurrence following prostatectomy and salvage radiation, using a case presentation of a

#ASCO25 abstracts titlkes are out!!!!! meetings.asco.org/meetings/2025-… Much Looking forward to seeing the exciting new data in GU tumors!!!! See you all in Chicago!!!! ASCO The ASCO Post Toni Choueiri, MD Tom Powles Shilpa Gupta Michiel vd Heijden Robert Motzer MD GUARD Consortium

GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC

⚠️ Retrospective analysis of >7,000 pts with high-risk #ERlow (1–10%) early #BreastCancer 🎀 shows that omission of adjuvant ET is linked to worse OS - especially in ER 6–10% or with residual disease after NAC ⚠️ 👉 ascopubs.org/doi/10.1200/JC… OncoAlert Journal of Clinical Oncology

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity In this review in ESMO Open we address this topic👇🏻 OncoAlert sciencedirect.com/science/articl…

Lutetium PSMA therapy in #mCRPC: Real-world evidence from #PRECISION data platform. Oliver Sartor, MD Mayo Clinic joins Zach Klaassen Georgia Cancer Center to discuss the PRECISION data platform, analyzing prompt vs. deferred lutetium PSMA therapy (#Pluvicto) in advanced

Key topics to watch in Thoracic Oncology at ASCO 2025 #ASCO25 #LungCancer #ThoracicOncology #CancerResearch

🚨CAO/ARO/AIO-12 + OPRA Rectal trials🚨 WW vs. Planned surgery after TNT for rectal Ca 🟰 OS, DFS, DM ‼️Comparable outcomes when matched for response (cCR vs. pCR, etc) 🙌Supports WW as a highly appropriate, pt-centric, option for patients with cCR after TNT

Nuevos mecanismos de acción en el manejo de Cáncer de Próstata (inhibidores de EZH2)

Treatment Algorithm: This is the algorithm to reference during our discussion w/ Ghassan Abou-Alfa on Biliary Tract Cancers! #OncTwitter #MedTwitter #gism PER